Novo Nordisk sees India as a key clinical trial hub for its range of novel therapies in lifestyle disorders and rare diseases

June 22, 2023

Novo Nordisk sees India to actively participate in its global clinical trials. India is an important destination for clinical trials because of several factors such an English speaking population, large-diverse patient pool, medical expertise, qualified research professionals, advanced healthcare infrastructure and a cost competitive advantage.
 
On its centenary year, the Denmark-based Novo Nordisk which was founded on June 21, 2023 reinstates its research commitment to diabetes, rare diseases, obesity and serious chronic disease.
 
Lars Fruergaard Jørgensen, CEO, Novo Nordisk shared the game-plan of the company to continue to help patients and society for generations to come with novel treatment options.
 
With technology adoption, Novo Nordisk is building on its legacy to innovate for future generations. A robust medical pipeline with drug candidates are at various stages of development covering pre-clinical to clinical trials and regulatory approvals, stated the company’s leadership team at an international virtual press briefing.
 
Mike Doustdar, EVP International Operations, Novo Nordisk and Camilla Sylvest, EVP commercial strategy and corporate affairs, Novo Nordisk stated that efforts were on to find new ways to help people living with obesity, a chronic disease that is an increasing burden on individuals, families as well as on the healthcare systems.
 
Novo Nordisk has India on its radar for clinical trials across cardiovascular diseases, rare diseases and haemophilia.
 
Post the event Vikrant Shrotriya, managing director and corporate vice president, Novo Nordisk India, said, “India actively participates and contributes to the global clinical trials. With nearly 4,500 employees, India houses nearly 8% of the global workforce. For this reason, India is also a major contributor to not just the commercial, but the research vertical of the company.
 
India’s contribution to the global clinical trials is 7-8%. Presently, India is part of 36 clinical trials comprising diabetes, obesity, haemophilia A, haemophilia with inhibitors, chronic kidney disease (CKD), cardiovascular diseases (CVD), non-alcoholic steatohepatitis (NASH), etc, said Shrotriya.

PHARMABIZ.com